Join to View Full Profile
12605 E 16th AveAurora, CO 80045
Phone+1 720-848-0000
Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of ColoradoResidency, Internal Medicine, 2005 - 2008
University of Texas Medical Branch School of MedicineClass of 2005
Certifications & Licensure
AZ State Medical License 2023 - 2027
CO State Medical License 2024 - 2027
SD State Medical License Active through 2027
OH State Medical License 2025 - 2027
WY State Medical License 2025 - 2026
TN State Medical License 2023 - 2026
ND State Medical License 2025 - 2026
American Board of Internal Medicine Medical Oncology- Join now to see all
Clinical Trials
- A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Start of enrollment: 2011 Dec 01
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
- Doxycycline, Temozolomide and Ipilimumab in Melanoma Start of enrollment: 2012 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff, Khalida Wani, Merrick I Ross
Journal of Clinical Oncology. 2025-07-10 - Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG ...Megan Othus, Elad Sharon, Michael C Wu, Vernon K Sondak, Antoni Ribas
Clinical Trials. 2025-03-18 - Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.Sapna P Patel, Rahul A Sheth, Christina Davis, Theresa Medina
Journal of Clinical Oncology. 2025-03-10
Journal Articles
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaRichard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
Press Mentions
Pembrolizumab for Advanced Melanoma: Is It Worth It?May 9th, 2025
Melanoma Survivor: Protect Your SkinMarch 19th, 2019- Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%October 25th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
